Alkermes plc
ALKS
Rankning i aktier
#2634
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aktiekurs
$43.05
Senast synkroniserad: 2026-10-19
Marknadsvärde
$7.22B
Förändring (1 dag)
4.43%
Förändring (1 år)
38.95%
Land
IE
Handel Alkermes plc (ALKS)
Kategori
Healthcare
Antal utestående aktier för Alkermes plc (ALKS)
Antal utestående aktier per June 2026: 166.61M
Enligt de senaste finansiella rapporterna och aktiekursen för Alkermes plc är det aktuella antalet utestående aktier 166.61M. I slutet av December 2023 hade företaget 166.22M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Alkermes plc (ALKS) från 2000 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 166.61M | 0.74% |
| 2024 | 165.39M | -0.50% |
| 2023 | 166.22M | 1.52% |
| 2022 | 163.74M | 1.74% |
| 2021 | 160.94M | 1.35% |
| 2020 | 158.80M | 1.12% |
| 2019 | 157.05M | 1.25% |
| 2018 | 155.11M | 1.11% |
| 2017 | 153.42M | 1.27% |
| 2016 | 151.48M | 1.53% |
| 2015 | 149.21M | 2.71% |
| 2014 | 145.27M | 10.30% |
| 2013 | 131.71M | 0.00% |
| 2012 | 131.71M | 14.83% |
| 2011 | 114.70M | 19.97% |
| 2010 | 95.61M | 0.81% |
| 2009 | 94.84M | -0.34% |
| 2008 | 95.16M | -5.54% |
| 2007 | 100.74M | 1.51% |
| 2006 | 99.24M | 9.03% |
| 2005 | 91.02M | 1.03% |
| 2004 | 90.09M | 9.76% |
| 2003 | 82.08M | 27.52% |
| 2002 | 64.37M | 1.10% |
| 2001 | 63.67M | 14.21% |
| 2000 | 55.75M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 52.39% |
US
|
|
| 396.00M | 137.68% |
US
|
|
| 478.91M | 187.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.68% |
NL
|
